MediWound

MediWound Ltd. is a global leader in developing enzymatic therapeutics for non-surgical tissue repair. Their approved product, NexoBrid®, is used for early burn eschar removal, while their pipeline includes EscharEx® for chronic wounds and MW005 for basal cell carcinoma. These innovative therapies aim to improve patient outcomes, reduce healthcare costs, and minimize the need for surgery.

Country
Israel
Founded
2000
Social
Source of information: 

mediwound.com

Add to My List
Key Executives

Ofer Gonen

Chief Executive Officer

Lior Rosenberg

Founder

Industries